Parkinson's Disease Clinical Trial
Official title:
Programming Strategy of Variable Frequency Stimulation for Gait Impairments in Parkinson's Disease
NCT number | NCT05905198 |
Other study ID # | K3438 |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | May 24, 2023 |
Est. completion date | March 1, 2024 |
Variable Frequency Stimulation(VFS) is a stimulation pattern applied in Deep Brain Stimulation(DBS) therapy for Parkinson's disease(PD). Peking Union Medical College Hospital was the first centre conducting research on VFS. The studies in the past have resembled conclusion that VFS provides improvement not only in the major symptoms such as tremor and rigidity, but also in gait and balance disorder. However, the best programming strategy of VFS has not met agreement. The random-controlled double blinded crossover study is designed for participants who underwent DBS surgery in bilateral subthalamic nucleus for parkinson's disease. The investigators study several strategies on programming and observe the improvement of symptom to look for the best one. A 4-month follow-up is designed to observe a relatively long-term effectiveness of VFS. The study intends to gather more clinical evidence to guide further studies on VFS application.
Status | Recruiting |
Enrollment | 30 |
Est. completion date | March 1, 2024 |
Est. primary completion date | December 31, 2023 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 75 Years |
Eligibility | Inclusion Criteria: - Idiopathic Parkinson's disease (according to the Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease); - 18-75 years of age; - Hoehn & Yahr = 3 (in best OFF-medication condition); - Implanted bilateral subthalamic nucleus DBS for over 1 year; - gait Impairments in OFF-medication condition; - High Frequency Stimulation provides significant improvement; - in OFF-medication On-stimulation condition, capable of walking = 10m. Exclusion Criteria: - mental disorder or dementia; - Pregnant women, lactating mothers or women who are unable to take effective measures to prevent pregnancy; - With other diseases that can affect walking distance, such as joint diseases of the lower body, spinal diseases, neuropathy, or serious heart or lung diseases; - In severe health condition, such as diseases associated with heart or liver; - Epilepsy; - Lead off target; - Unable to willingly sign Written informed Consent; - Disagree or unable to cooperate with follow-up sessions. |
Country | Name | City | State |
---|---|---|---|
China | Peking Union Medical College Hospital | Beijing |
Lead Sponsor | Collaborator |
---|---|
Peking Union Medical College Hospital |
China,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change from Baseline 5m-Timed Up and Go test Time Result at 2 months. | Conduct a TUG test with 5m range setting and measure the time cost | Baseline, 2 months | |
Primary | Change from Baseline 5m-Timed Up and Go test Time Result at 4 months. | Conduct a TUG test with 5m range setting and measure the time cost | Baseline, 4 months | |
Secondary | Change from Baseline 5m-Timed Up and Go test Step Frequency at 2 months. | Conduct a TUG test with 5m range setting and measure the step movement and calculate the step frequency | Baseline, 2 months | |
Secondary | Change from Baseline 5m-Timed Up and Go test Step Frequency at 4 months. | Conduct a TUG test with 5m range setting and measure the step movement and calculate the step frequency | Baseline, 4 months | |
Secondary | Change from Baseline 5m-Timed Up and Go test Length at 2 months. | Conduct a TUG test with 5m range setting and measure the length of each step | Baseline, 2 months | |
Secondary | Change from Baseline 5m-Timed Up and Go test Step Length at 4 months. | Conduct a TUG test with 5m range setting and measure the length of each step | Baseline, 4 months | |
Secondary | Change from Baseline 5m-Timed Up and Go test Step Variation Coefficient at 2 months. | Conduct a TUG test with 5m range setting and use the length of each step to calculate the difference coefficient | Baseline, 2 months | |
Secondary | Change from Baseline 5m-Timed Up and Go test Step Variation Coefficient at 4 months. | Conduct a TUG test with 5m range setting and use the length of each step to calculate the difference coefficient | Baseline, 4 months | |
Secondary | Change from Baseline Movement Disorder Society Unified Parkinson's Disease Rating Scale part III score at 2 months. | Conduct a Movement Disorder Society Unified Parkinson's Disease Rating Scale survey and record the score. Higher MDS UPDRS III score represents worse movement disorder symptoms. | Baseline, 2 months | |
Secondary | Change from Baseline Movement Disorder Society Unified Parkinson's Disease Rating Scale part III score at 4 months. | Conduct a Movement Disorder Society Unified Parkinson's Disease Rating Scale survey and record the score. Higher MDS UPDRS III score represents worse movement disorder symptoms. | Baseline, 4 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT02915848 -
Long-term Stability of LFP Recorded From the STN and the Effects of DBS
|
||
Recruiting |
NCT03648905 -
Clinical Laboratory Evaluation of Chronic Autonomic Failure
|
||
Terminated |
NCT02688465 -
Effect of an Apomorphine Pump on the Quality of Sleep in Parkinson's Disease Patients (POMPRENELLE).
|
Phase 4 | |
Completed |
NCT05040048 -
Taxonomy of Neurodegenerative Diseases : Observational Study in Alzheimer's Disease and Parkinson's Disease
|
||
Active, not recruiting |
NCT04006210 -
Efficacy, Safety and Tolerability Study of ND0612 vs. Oral Immediate Release Levodopa/Carbidopa (IR-LD/CD) in Subjects With Parkinson's Disease Experiencing Motor Fluctuations
|
Phase 3 | |
Completed |
NCT02562768 -
A Study of LY3154207 in Healthy Participants and Participants With Parkinson's Disease
|
Phase 1 | |
Completed |
NCT00105508 -
Sarizotan HC1 in Patients With Parkinson's Disease Suffering From Treatment-associated Dyskinesia
|
Phase 3 | |
Completed |
NCT00105521 -
Sarizotan in Participants With Parkinson's Disease Suffering From Treatment Associated Dyskinesia
|
Phase 3 | |
Recruiting |
NCT06002581 -
Repetitive Transcranial Magnetic Stimulation(rTMS) Regulating Slow-wave to Delay the Progression of Parkinson's Disease
|
N/A | |
Completed |
NCT02236260 -
Evaluation of the Benefit Provided by Acupuncture During a Surgery of Deep Brain Stimulation
|
N/A | |
Completed |
NCT00529724 -
Body Weight Gain, Parkinson, Subthalamic Stimulation
|
Phase 2 | |
Active, not recruiting |
NCT05699460 -
Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy
|
||
Completed |
NCT03703570 -
A Study of KW-6356 in Patients With Parkinson's Disease on Treatment With Levodopa-containing Preparations
|
Phase 2 | |
Completed |
NCT03462680 -
GPR109A and Parkinson's Disease: Role of Niacin in Outcome Measures
|
N/A | |
Completed |
NCT02837172 -
Diagnosis of PD and PD Progression Using DWI
|
||
Not yet recruiting |
NCT04046276 -
Intensity of Aerobic Training and Neuroprotection in Parkinson's Disease
|
N/A | |
Recruiting |
NCT02952391 -
Assessing Cholinergic Innervation in Parkinson's Disease Using the PET Imaging Marker [18F]Fluoroethoxybenzovesamicol
|
N/A | |
Active, not recruiting |
NCT02937324 -
The CloudUPDRS Smartphone Software in Parkinson's Study.
|
N/A | |
Completed |
NCT02874274 -
Vaccination Uptake (VAX) in PD
|
N/A | |
Completed |
NCT02927691 -
Novel Management of Airway Protection in Parkinson's Disease: A Clinical Trial
|
Phase 2 |